Speaker Interview with aptaTargets released

SAE Media Group reports: Macarena Hernandez-Jimenez from aptaTargets S.L. discusses the challenges and breakthroughs in the oligonucleotide therapeutics field
By: SAE Media Group
 
LONDON - Aug. 3, 2022 - PRLog -- The Oligonucleotide Therapeutics and Delivery Conference, taking place on the 21st and 22nd September 2022 in London, UK, will reveal the latest in oligonucleotide discovery and delivery, with presentations on targeted delivery mechanisms, oligonucleotide chemistries and important clinical advances.

Interested parties can register at: http://www.oligonucleotide.co.uk/PR3PRLOG to view the full agenda and speaker line-up.

SAE Media Group caught up with Macarena Hernandez- Jimenez, Chief Scientific Officer, aptaTargets S.L., speaking on day two of the conference, to discuss about her challenges, upcoming projects and breakthroughs within the oligonucleotide therapeutics industry.

The oligonucleotide therapeutics market has grown rapidly over the past few years, what key difference have you noticed in the last year regarding significant developments?

Well, of course, I think that the main difference is the development of RNA-based vaccines that has put oligonucleotides in the middle of the therapeutic arena. I think this is a very positive advance in the oligonucleotide therapeutics.

What do you see as the greatest challenge for you to overcome personally in the oligonucleotide field at the moment?

For me, the main challenge has been to convince regulatory agencies. Few years ago, some of them were not familiar with oligonucleotides and it was quite difficult all the regulatory management.

What current hot topic will you be addressing in your presentation and what would you say makes it relevant to 2022?

The most important point in my presentation is that we have finished the recruitment of patients from APRIL trial, a Phase Ib/IIa clinical trial in stroke patients. I hope I will show some preliminary results.

To read the full speaker interview please visit: http://www.oligonucleotide.co.uk/PR3PRLOG

For sponsorship opportunities, please contact Andrew Gibbons on +44 (0) 20 7827 6156 or email: agibbons@smi-online.co.uk

For media enquiries or a press pass contact Marketing, Nikisha Galoria on +44 (0) 20 7827 6154 or email ngaloria@smi-online.co.uk

2nd Annual Oligonucleotide Therapeutics & Delivery Conference

21-22 September 2022

London, UK

Sponsors & Exhibitors: Catalent | ChemGenes | NOF Corporation | Wuxi App Tech

http://www.oligonucleotide.co.uk/PR3PRLOG

Contact
Nikisha Galoria
***@smi-online.co.uk
End
Email:***@smi-online.co.uk
Posted By:***@smi-online.co.uk Email Verified
Tags:Oligonucleotide
Industry:Medical
Location:London City - London, Greater - England
Subject:Events
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
SMi Group Ltd. News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share